HIV prevention study for young people in Brazil
Part of Infections clinical trials.
This study tests if getting HIV prevention medication (PrEP) from a trained peer in your community works as well as getting it from a clinic. It is for young people aged 15 to 24 who are sexually active and not yet using PrEP.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 15 and 24 years old
- Sexually active
- Not currently taking PrEP (HIV prevention pills)
- Willing to talk about taking PrEP pills
- Agree to be placed in either the peer-led or standard clinic group
- Do not have HIV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study helps connect young people aged 13–24 to PrEP, a daily pill that prevents HIV. It tests whether offering PrEP in clinics or community locations makes it easier for you to get and stay on this prevention medication.
This study tests a program called PrEP Choice to help young people learn about and start PrEP, a daily pill that prevents HIV. It aims to see if offering choices in PrEP care makes it easier to use.
This study is for cis-gender men who are HIV-negative and at risk for HIV. It tests a program to help you start and stay on PrEP (medication to prevent HIV).
This study helps people at higher risk of HIV get access to PrEP, a daily medication that prevents HIV infection. The program focuses on underserved communities in Rio de Janeiro and aims to make PrEP easier to access and use.
This study tests better ways to find and treat HIV in young people (ages 15-24) in Nigeria. It offers either HIV prevention medicine (PrEP) if you are HIV-negative, or HIV treatment if you are newly diagnosed with HIV.
This study tests a program to help adolescent girls and young women at high risk of HIV take PrEP consistently. It aims to improve access and adherence to PrEP, a daily pill that prevents HIV.
Hear when a new Pre-Exposure Prophylaxis (PrEP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.